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Abstract
Background: Recruiting asymptomatic participants with early disease stages into studies is challenging and only
little is known about facilitators and barriers to screening and recruitment of study participants. Thus we assessed
factors associated with screening rates in the MACUSTAR study, a multi-centre, low-interventional cohort study of
early stages of age-related macular degeneration (AMD).
Methods: Screening rates per clinical site and per week were compiled and applicable recruitment factors were
assigned to respective time periods. A generalized linear mixed-effects model including the most relevant
recruitment factors identified via in-depth interviews with study personnel was fitted to the screening data. Only
participants with intermediate AMD were considered.
Results: A total of 766 individual screenings within 87 weeks were available for analysis. The mean screening rate
was 0.6 ± 0.9 screenings per week among all sites. The participation at investigator teleconferences (relative risk
increase 1.466, 95% CI [1.018–2.112]), public holidays (relative risk decrease 0.466, 95% CI [0.367–0.591]) and
reaching 80% of the site’s recruitment target (relative risk decrease 0.699, 95% CI [0.367–0.591]) were associated
with the number of screenings at an individual site level.
Conclusions: Careful planning of screening activities is necessary when recruiting early disease stages in multi-
centre observational or low-interventional studies. Conducting teleconferences with local investigators can increase
screening rates. When planning recruitment, seasonal and saturation effects at clinical site level need to be taken
into account.
Trial registration: ClinicalTrials.gov NCT03349801. Registered on 22 November 2017.
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Background
Recruiting asymptomatic participants with early disease
stages into clinical or epidemiological studies is challen-
ging because these individuals might not be aware of
their disease and their perceived disease burden is often
low. In order to overcome these challenges, careful plan-
ning of screening and recruitment activities is crucial.
This includes careful evaluation of screening and recruit-
ment facilitators as well as barriers. A number of studies
have reported factors that impact recruitment at differ-
ent levels [1–7], but knowledge about how to best iden-
tify the specific target population of asymptomatic
participants with early disease stages into studies re-
mains limited. Against this background we assessed the
recruitment process and any measures which impacted
screening numbers in a study of early, largely asymp-
tomatic stages of age-related macular degeneration
(AMD). Our goal was to retrospectively identify facilita-
tors and barriers to screenings from a sponsor’s perspec-
tive in a multi-center cohort study of early disease
stages.
The reason for addressing early AMD stages in clinical
research today is to reduce the signicficant burden of
late-stage AMD by developing novel interventions that
stop or delay progression from early AMD stages to late
AMD and prevent potentially irreversible loss of vision
which make late AMD a leading cause of visual loss in
industrialised countries [8, 9]. Early stages of AMD pro-
gress slowly at an estimated rate of 5–20 per 100
person-years to late AMD [10] and frequently cause no
or only little symptoms [11, 12]. Similar to other early
disease stages such as early Alzheimer’s disease, predia-
betes or pre-clinical cancer [13–15], individuals with
early stages of AMD are frequently not aware of their
disease [16]. This makes it important to investigate
which measures facilitate or impede screening activities
for clinical studies of early AMD as identified factors are
of potential relevance to other studies recruiting asymp-
tomatic participants. We herein report the impact of
both facilitators and barriers to screening participants
for the MACUSTAR study, a multi-national cohort
study focusing on the most high-risk early stage of AMD
(“intermediate AMD”) from a sponsor’s perspective [17].
Methods
The MACUSTAR study
The MACUSTAR study is a multi-centre cohort study
focusing mainly on “intermediate AMD”, a high-risk
type within the early AMD stages. The main study ob-
jective is the development of new candidate endpoints
for intermediate AMD clinical trials. For this purpose,
participants at all AMD disease stages (no, early, inter-
mediate and late AMD) undergo a battery of functional
tests and imaging procedures and several patient-
reported outcome measures are administered. The ma-
jority of participants of the MACUSTAR study has inter-
mediate AMD and was recruited at 20 study sites while
the other groups (early AMD, late AMD, no AMD) were
recruited only at five study sites. More details on the
study protocol including the eligibility criteria, visit
schedule, outcome measures and their assessment, con-
founders, sources of bias and sample size considerations
have been published previously [18].
Recruitment for the MACUSTAR study started in
March 2018 and lasted for 87 weeks. Patients were
screened and recruited at 20 ophthalmological clinical
sites in seven European countries (Denmark, France,
Germany, Italy, Netherlands, Portugal and United King-
dom). Five of them were academic core partners within
the MACUSTAR consortium, the other sites were affili-
ated with the consortium and members of the European
Vision Clinical Research Network (EVICR.net). To facili-
tate planning of screenings, all sites confirmed their abil-
ity to recruit a minimum of 20 individuals into the
MACUSTAR study before study initiation; the core part-
ners agreed to a higher target of 40–70 recruited partici-
pants. Herein we retrospectively analyse and report the
impact of screening measures, and other factors found
to be either facilitators or barriers to screening
participants.
All institutional ethic committees approved the study
and participants gave written informed consent prior to
participation. The MACUSTAR project receives funding
from the European Union Innovative Medicines Initia-
tive (IMI2) Horizon 2020 programme. It has been regis-
tered at the website clinicaltrials.gov with the identifier
NCT03349801. Inclusion criteria for this analysis were
individuals screened for the MACUSTAR study with the
screening diagnosis intermediate AMD, a high-risk type
of the early AMD stages (determined at the clinical site).
Study inclusion at all study sites was based on the evalu-
ation and confirmation of AMD diagnosis by a central
reading centre, as described previously [17]. Exclusion
criteria were missing informed consent, participation in
any of the other MACUSTAR study groups (early, or late
AMD or control group) or relocation to another clinical
site within the time of the study. The MACUSTAR clin-
ical study is managed by the academic clinical research
organization AIBILI (Association for Innovation and Bio-
medical Research on Light and Image, www.aibili.pt) and
monitored by the European distributed infrastructure net-
work ECRIN-ERIC (www.ecrin.org).
Qualitative evaluation of screening measures
Screening strategies and measures were planned cen-
trally by a coordination team and then implemented
through AIBILI and ECRIN-ERIC across all sites. In
order to be able to systematically assess the impact of
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any of these on screening numbers, we extracted all rele-
vant information retrospectively from the study protocol,
protocol amendments, clinical site communications such
as newsletters and briefings, status reports, meeting mi-
nutes and emails from March 2018 to March 2020. All
factors that may have contributed to screening rates
were compiled and assigned to time periods and clinical
sites within the recruitment phase of the study where
they had been implemented. Time is measured in weeks
since the first site opened. Furthermore, we conducted
four in-depth interviews with personnel actively involved
in the study (clinical project managers, study site coordi-
nators and research personnel) to identify the most rele-
vant screening factors based on the available screening
numbers and factors previously identified. The inter-
views consisted of two parts to identify additionally rele-
vant factors: Firstly, all interviewed persons were asked
to name which factors (a) facilitated screenings or (b)
impeded screenings. Secondly, the factors were ranked
by the perceived impact on screening numbers by each
person interviewed. All persons were interviewed once
and only qualitative methods were applied during this
step.
Screening data compilation
Due to the availability of devices, ethics approvals, con-
tracting and the necessity to implement the upcoming
European Union General Data Protection Regulation in
2018, the first participants were screened at different
time points at the participating study sites. After com-
pletion of recruitment, data from the electronic case re-
port form and imaging data were collected and cleaned
as reported in the study protocol [18]. Screening num-
bers and recruitment numbers were compiled per clin-
ical site and per week. We assigned week 1 to the first
week of recruitment at the first site and used a global
consecutive numbering of weeks for all sites. Factors
that were considered relevant in the qualitative evalu-
ation (listed chronologically and preceded by a # sign in
the results) were assigned to specific clinical sites and to
specific time periods within the screening number data-
base based on where and when they were implemented
or occurred.
Statistical modelling
We explored the relationship between different screen-
ing factors and screening numbers per week at each clin-
ical site. The inter-correlation of recruitment factors was
assessed using Pearson correlation coefficients. When
two variables correlated with r > 0.8, only the factor
more strongly associated with screening numbers in
qualitative evaluation was used for further analyses. To
account for repeated measurements within the study
sites, a generalized mixed-effects model was built to
investigate the effect of screening factors on the screen-
ing numbers per site. As the official start of the recruit-
ment phase was scheduled at different time points for
each clinical site, a random intercept depending on the
site’s activity status was included. Each selected screen-
ing factor entered the model as a fixed effect. To capture
a possible time-trend, the week number (measured in
weeks since first site has opened) was also considered as
a fixed linear effect. Since the screening numbers can be
treated as count data, we used the Poisson family with a
logarithmic link function. Associations between screen-
ing numbers and factors contributing to screening num-
bers are presented in terms of relative risk increases
(exp(β)) with 95% confidence intervals, where β denotes
the coefficient estimate obtained from the mixed-effects
Poisson model.
The analyses were performed with the software R, ver-
sion 3.6.1 (R Core Team 2020, Vienna, Austria), using
the packages lme4 and MuMIn [19, 20].
Results
The overall number of screenings for the intermediate
AMD group was 767 in 87 weeks. One participant was
excluded from the analysis due to relocating after the
screening visit. The last site was opened for recruitment
37 weeks after the first site (Fig. 1). The mean screening
rate was 0.6 ± 0.9 screenings per week among all sites.
At total of 584 participants of the 766 individuals with
intermediate AMD included in the analysis (76%) were
included in the MACUSTAR study.
Qualitative evaluation
Twenty factors with a possible impact on patient screen-
ings were identified at global study level (Table 1). While
some of them occurred continuously, others were linked
to specific periods of time.
Screenings in the MACUSTAR study proceeded in
three phases. During an initiation period (weeks 1–25),
the overall screening trend increased and most partici-
pating clinical sites were successively opened for recruit-
ment (factor #1). The weekly screening numbers
increased noticeably after the summer holiday season of
2018 (#2). Several screening / recruitment measures im-
plemented continuously throughout the MACUSTAR
study were initiated in this period, including the recruit-
ment of patients from pre-screening lists, use of dissem-
ination material and a study newsletter as well as
individual contacts with investigators (i.e. phone calls
and emails to the principal investigator).
In the ensuing execution period (weeks 26–60) weekly
screening numbers varied more (range: 0–25 total
screenings per week). The implemented measures at the
beginning of the execution period included an increase
of participant travel expenses reimbursement from initial
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EUR 50 per visit to EUR 75 per visit (#3), an increased
MACUSTAR newsletter distribution frequency from
monthly to biweekly (#4) and the initiation of regular
coordination teleconferences with the project manage-
ment and monitors (#5). Three teleconferences with the
principal investigators (#6) were conducted during the
execution period and screening numbers increased after
these teleconferences. The teleconferences were used to
provide data from recent interim analyses to the study
staff (principle investigators, study coordinators, study
technicians) as well as to allow anyone to ask questions
and share approaches on common organizational hur-
dles, such as the organization of the study schedule,
feedback on why screenings failed or pitfalls in the re-
cruitment. Two in person investigator meetings (#7)
were also followed by an increase in weekly screenings.
The recruitment period was extended beyond the initial
end in week 48 until week 87 in order to meet recruit-
ment targets. The two lowest weekly screening rates in
the execution period (weeks 39 and 56) coincided with
Christmas 2018 and the planned end of recruitment be-
fore being extended.
The third phase of screenings was a transition period
(weeks 61–87). It was characterized by more steady
screening rates. The number of weekly screenings de-
creased in the summer holiday season 2019 but in-
creased noticeably afterwards. A change in the inclusion
criteria (#8), which opened up recruitment for individ-
uals with unilateral intermediate AMD, was associated
with an increase of the screenings at the end of the re-
cruitment period before the transition to the follow-up
phase of the study.
At the single clinical site level, the cumulative screen-
ings followed two different patterns. At eight sites, this
development increased continuously while at 12 sites, a
saturation of the screening rates towards the end of the
recruitment period was observed (#9). The core partner
sites reached higher recruitment rates (overall median
recruitment per site: 66 people) than the other clinical
sites (overall median recruitment per site: 29 people;
#10).
Variable selection process
Three of the 10 global variables identified (Table 1) were
highly correlated (#3 – #5; increase of travel expenses
reimbursement, increase of newsletter frequency, initi-
ation of regular coordination teleconferences with the
project management and monitors). In the in-depth
Fig. 1 Participants screened and participants eligible for the MACUSTAR study with intermediate age-related macular degeneration as well as
number of active sites and factors impacting screenings, displayed per week since start of recruitment at the first study site (80% target reached
refers to individual clinical sites; all other factors are global). The blue curves represent cumulative numbers; the grey curve represents numbers
per week
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interviews (see above), higher travel expenses reimburse-
ments were considered to have the largest impact on the
overall screening numbers and we therefore included
this factor in the multivariable model only. Thus, we
identified the following eight parameters for further stat-
istical evaluation in a multivariable model: Modification
of inclusion criteria, increase of participant travel ex-
penses reimbursement, organization of investigator tele-
conferences and meetings in person, public holidays,
saturation of screening numbers (80% of overall recruit-
ment per site), week and being a core partner in the
MACUSTAR consortium.
Multivariable screening number model
A mixed-effects model including the variables identified
qualitatively, excluding highly correlated variables (fac-
tors #1 – #3, #6 – #10, Table 1) was fitted to the screen-
ing data. The participation at investigator
teleconferences, public holidays and reaching a high pro-
portion (80%) of the site recruitment target showed
strong associations with screening rates at an individual
site level (Table 2). The conditional R2 value of the
model was 0.95 [19, 20]. According to this modelling ap-
proach, expected screening numbers increased by the
factor exp.(β) = 1.466 (95% CI [1.018–2.112]) after inves-
tigator teleconferences were implemented, decreased by
the factor exp.(β) = 0.446 (95% CI [0.367–0.591]) during
public holidays and decreased with a factor of exp.(β) =
0.669 (95% CI [0.367–0.591]) after a site reached 80% of
their recruitment target (after adjusting for the other
factors included in the model). This is in line with the
average screenings per week, which increased from 0.56
to 0.97 at the time of investigator teleconferences. They
decreased from 0.65 to 0.29 during holiday periods and
from 0.67 to 0.40 when individual sites reached 80% of
their recruitment target.
Discussion
In the MACUSTAR study, we successfully recruited a
large cohort of participants with early, mostly asymp-
tomatic AMD stages and found that constant interaction
with clinical sites including newsletters, investigator
meetings, teleconferences, individual contacts and trou-
bleshooting improve overall recruitment performance.
Out of this flurry of activities, however, regular investi-
gator teleconferences were the only measure which was
significantly associated with increased screenings at site
level. As was to be expected, public holidays were associ-
ated with decreased screening performance. Sites slowed
down screenings when they reached 80% of their recruit-
ment target. In summary, regular interactions with the
site investigators are crucial for a smooth recruitment,
and this should likely be increased once sites need to re-
cruit the last 20% as this was when screenings slowed
down again.
Table 1 Relevant global screening factors identified for the MACUSTAR study in qualitative evaluation ordered by estimated
magnitude of impact on screening numbers
Screening
measures
Factors prioritized in qualitative interviews* Other factors
All sites Change of inclusion criteria (opening for individuals with
unilateral intermediate disease) (#8)
Dissemination material (patient flyer, referral letter, study
procedure flyers, sample visit schedules)
Increase of participant travel expenses reimbursement (#3) Distribution of study newsletter
Investigator teleconferences (#6)
Investigator meetings (conferences) (#7) Letter of appreciation for clinical sites at recruitment start
Increase of study newsletter frequency (monthly to biweekly) (#4) Implementation of a clinical site questionnaire to identify
unsolved issues
Regular coordination teleconferences with the project
management and monitors (#5)
Single sites Pre-screening lists
Individual contacts with investigators (e-mail, phone, in person)
Individual contacts with site coordinators
Appearing in the newsletter as a “top recruiter”
Interacting
factors
Public holiday (#2) Competitive recruitment
Reaching a high proportion of the initial “recruitment target” or
exceeding this target (#9)
Communication of recruiting problems by individual sites
Successive initiation of screening activity (#1) Problems with study devices at individual sites
Consortium core membership (#10)
* only global factors that could be assigned to specific time periods were allowed
Factors preceded by a # sign were considered relevant in the qualitative evaluation and are displayed in the ranking order obtained in the qualitative evaluation
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Failure to recruit a sufficient number of participants in
any study can have dire consequences. In an evaluation
of two funding agencies, 36% of 195 trials reached less
than 80% of their recruitment targets, resulting in a re-
duced power which had medical, scientific, financial and
ethical implications [21, 22]. In addition, low recruit-
ment is a frequent cause for early termination of clinical
studies [23]. Careful recruitment planning is therefore
an absolute necessity in all clinical studies. In MACUS-
TAR, no single measure resulted in successful comple-
tion of recruitment alone. This is in keeping with
available literature where it has previously been noted
that only a combination of recruitment measures can
lead to successful completion of study recruitment [24].
A review and meta-analysis of recruitment facilitators
identified telephone reminders to non-responding candi-
date participants as a significant facilitator of recruit-
ment to randomized controlled trials [1]. We assume
that one of the mediators of this effect was that partici-
pants were encouraged to allocate their resources in
ways that supported the studies. Similarly, teleconfer-
ences with the investigators had a significant positive
impact on the MACUSTAR screenings in a multi-site
setting. In our experience, teleconferences as well as in-
dividual calls allow for a personal relationship and multi-
or bidirectional conversations with the site staff on e.g.
goals and site-specific difficulties. It also supports peer
group learning and creates a common sense of responsi-
bility for the study. In contrast to our findings, Caldwell
et al. did not find significantly increased recruitment
when keeping increased contact with investigators [2].
Screening rates for the MACUSTAR study dropped
significantly during public holidays. This result has not
been reported in the available literature [1–3, 5, 21, 25–
29] but seems self-evident as facilities are closed during
holidays. Gkioni and colleagues reviewed models for the
prediction of recruitment when trials are designed [6].
They described that seasonal variations were considered
by only 17% of the predictive models found in the litera-
ture. We observed high absolute increases in weekly
screenings shortly after the end of holiday periods. This
finding could be of strategic value for the initiation of re-
cruitment measures in other clinical studies. We assume
that facilitating recruitment with new measures could be
particularly effective after public holidays.
Besides the assumed influence of teleconferences and
public holidays, we observed significant saturation effects
of screening numbers in the MACUSTAR study. These
would be expected in a study with committed recruit-
ment goals for each clinical site. However, with competi-
tive recruitment in the MACUSTAR study this was an
unexpected finding and future research is needed to fur-
ther assess this effect. In terms of practical implications,
sponsor contact should be increased for clinical sites
which have almost reached their recruitment target.
Besides these global factors which were present or im-
plemented across all clinical sites in this study, site spe-
cific factors such as existing referral networks or a
history of clinical research projects are likely to impact
screenings numbers and recruitment as well. Unfortu-
nately, it is impossible to assess the impact of any site-
specific factors in a systematic fashion as they cannot be
quantified across sites.
The main strengths of our analysis include its qualita-
tive and quantitative research methodology, its focus on
multi-centre epidemiological research and its inclusion
of recruitment factors also identified by previous studies
following a thorough review of the literature. We fo-
cused our analysis on screening numbers on a site level.
Recruitment was not directly assessed in our model
since recruited participants out of the pool of screenings
were determined by a central reading centre, not by the
local investigator. The main limitation of our study is its
retrospective character and thus limited generalizability
to other studies. As the very few previous studies on re-
cruitment facilitators were done in controlled
Table 2 Model parameters for the screening numbers per week in a multivariable generalized mixed-effects model (Poisson family
with logarithmic link function)
Predictor β coefficient* exp (β)* 95% interval for exp(β)* p value
Revision of inclusion criteria 0.186 1.204 (0.881–1.647) 0.243
Increase of travel expenses reimbursement 0.149 1.161 (0.859–1.570) 0.331
Investigator teleconferences 0.382 1.466 (1.018–2.112) 0.0398
Investigator meetings −0.084 0.919 (0.705–1.199) 0.534
Core partner site 0.379 1.460 (0.254–8.392) 0.671
Reaching 80% of site recruitment target −0.357 0.699 (0.542–0.903) < 0.001
Public holidays −0.763 0.466 (0.367–0.591) < 0.001
Week −0.006 0.994 (0.986–1.003) 0.202
Intercept −4.19 0.015 (0.005–0.045)
* adjusted values. No evidence for overdispersion was found (dispersion parameter: 1.0098, p = 0.3820 [19]). Only a shared fixed intercept is added when the site
is inactive (β0 = − 4.19, exp.(β0) = 0.015, 95% CI [0.005–0.045]). Random intercepts α for active clinical sites ranged from 3.42 to 4.35
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interventional trials, our results from this observational
study have to be interpreted with caution but add to the
existing literature. In addition, our analyses provide valu-
able information in particular relevant to studies recruit-
ing difficult to recruit populations such as early and
asymptomatic disease stages [30].
In conclusion, many different facilitators and barriers
likely interacted during the recruitment phase of the
MACUSTAR study, a multi-site cohort study of early
stages of AMD. Regular teleconferences with site investi-
gators increased while public holidays and screening ac-
tivity saturation at individual clinical sites decreased
screening performance. These factors should be given
special attention in the design and conduction of future
studies as well as selection of clinical sites in particular
when recruiting participants with early and largely
asymptomatic disease stages.
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